PR Newswire Clinical TrialsOriginal article
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
ConferenceTissueCypherPositive
AI Analysis
Summary
Castle Biosciences presented data at ACG 2026 demonstrating that TissueCypher molecular risk assessment can identify elevated progression risk in Barrett's Esophagus beyond standard pathology findings, potentially informing surveillance and treatment decisions.
Importance:5/10
Sentiment:
0.60
molecular diagnosticsBarrett's Esophagusrisk assessmentACG 2026conference data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 12, 2026 8:30 PM